N/A N=478 EU Safety and Efficacy Study Regarding the R3 Acetabular Hip System
Degenerative Joint Disease
Primary: Implant Survivorship — 0.89 percentage of hips
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=42 Evaluation of the Effectiveness of Extracorporeal Shockwave Therapy in Patients With Patellar Tendinopathy on Its Micromorphology
Patellar Tendinopathy
Primary: Change in Peak Spatial Frequency Radius at the Site of Pathology — 2.119; 2.234 mm
N/A N=20 VANISH for Chronic Low Back Pain
Chronic Low-back Pain
Primary: Assessment of Opioid Use Via Subject Report — 47.5; 21.75 morphine milligram equivalent
N/A N=116 Friendship Bench Mental Health Intervention for Adolescent Girls and Young Women in South African PrEP Delivery Settings
Depression · Pre-Exposure Prophylaxis
Primary: PrEP Adherence at Week 12 — 29; 22 Participants — p=0.44
Phase 3 N=8,057 Study of a Single Intramuscular Dose of Nirsevimab in the Prevention of Hospitalizations Due to Respiratory Syncytial Virus (RSV) Infection in Healthy Term and Preterm Infants During the First Year of Life
RSV Immunization · Healthy Volunteer
Primary: Number of Participants With Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Infection (LRTI) Hospitalization Through the Respiratory Syncytial Virus Season…
N/A N=115 QuitGuide for American Indians: Aims 2 & 3
Tobacco Use · Tobacco Use Disorder
Primary: Frequency of App Use — 15.3; 14.9; 4.3; 3.7 App initiations per day
N/A N=80 Preventing Levodopa Induced Dyskinesia in Parkinson's Disease With HMG-CoA Reductase Inhibitors
Parkinson Disease · Dyskinesia, Drug-Induced
Primary: Peak Unified Dyskinesia Rating Score (UDysRS) — 10.9; 10.8; 13.2 score on a scale — p=0.63
Phase 1 N=56 Evaluation of Two Zika Viruses for Use in Controlled Human Infection Models (CHIM)
Zika Virus
Primary: Number of Solicited Adverse Events — 1; 0; 0; 0 events
Phase 2 N=132 GLS-1027 for the Prevention of Severe Pneumonitis Caused by SARS-CoV-2 Infection (COVID-19)
Pneumonitis · SARS-CoV Infection
Primary: Number of Serious Adverse Events Relative to Treatment Group — 1; 3; 0 participants
N/A N=150 Neuromuscular Intervention Targeted to Mechanisms of ACL Load in Female Athletes
Rehabilitation · ACL Reconstruction
Primary: Number of Participants With Second ACL Injury — 3; 7; 5 Participants
N/A N=22 Cold Milk for Dysphagia in Preterm Infants
Dysphagia of Newborn
Primary: Percentage of Infants With Improvement of Dysphagia — 58 Percentage of patients
Phase 1 N=57 Study of Avelumab-M3814 Combinations
Oncology · Solid Tumors
Primary: Part A: Number of Participants Who Experienced Dose Limiting Toxicities (DLTs) Assessed Using National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events…
N/A N=14,490 Smart Discharges for Mom & Baby
Maternal Sepsis · Neonatal Sepsis
Primary: Post-discharge Readmission or Mortality — 231; 349 Participants
N/A N=89 Distal Targeter vs Free-hand
Femur Fracture · Tibial Fractures · Nonunion of Fracture
Primary: Patient Radiation Exposure — 47.03; 10.24 images taken
N/A N=60 Technology-Based Intervention to Promote Heart Health After Cardiac Rehab (Mobile4Heart)
Ischemic Heart Disease · Unstable Angina · Systolic Heart Failure
Primary: Steps Per Day — 8860; 6633 Steps/day